Diffuse Large B-Cell and Mantle Cell Lymphoma
Conditions
Interventions
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients who meet the following criteria will be included in Cohort 1: • Patient had a confirmed diagnosis of DLBCL or ICD-10:C83. 3; • Patient was=18 years on the index date; • Patient received at least one regimen of lymphoma-related therapy between 1st July 2017 and 31st Dec 2022. (Lymphoma-related regimen including Systemic therapy, RT, HSCT) Patients who meet the following criteria will be included in Cohort 2: • Patient had a confirmed diagnosis of MCL or ICD- C83. 1; • Patient was=18 years on the index date; • Patient received at least one regimen of lymphoma-related therapy between 1st July 2017 and 31st Dec June 2022. (Lymphoma-related regimen including Systemic therapy, RT, HSCT)
Exclusion criteria
Exclusion criteria: • Patient has a minimal follow-up period less than six months; • Patients who took part in an interventional clinical trial for the treatment of DLBCL and MCL in first three lines of therapy. • Patient has received lymphoma-related MSD product/product class therapy during the eligibility period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proportion of treatment regimens in DLBCL and MCL patients by line of therapies;proportion of BTKi usage in all patients by different patient characteristics; | — |
Secondary
| Measure | Time frame |
|---|---|
| real-world duration of treatment(rwDOT), real-world time to next treatment(rwTTNT), real-world progression-free survival (rwPFS), and Overall survival (OS) by lines of therapy ; | — |
Countries
China
Contacts
Public ContactYuqin Song
Beijing Cancer Hospital
Outcome results
None listed